Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma
The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations. The FGFR TKI erdafitinib (Balversa) continued to provide consistent clinical benefits with a manageable safety profile...
www.onclive.com
Comments / 0